AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek t

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Related Keywords

Cleveland , Ohio , United States , Leland Metheny , Oncology Program At Case Comprehensive Cancer Center , University Hospitals Cleveland Medical Center , Case Western Reserve University School Of Medicine , Case Western Reserve University School , Immune Oncology Program , Case Comprehensive Cancer Center , Hematologic Oncology , D , Lymphoma , Myeloma , Aml , Wall , Glioblastoma Multiforme ,